探讨新辅助化疗在晚期卵巢癌治疗上的临床应用价值

To Explore the Clinical Value of Neoadjuvant Chemotherapy in the Treatment of Advanced Ovarian Cancer

目的探讨新辅助化疗在晚期卵巢癌中的应用效果。方法整取抽样2013年1月至2016年1月我院收治的100例晚期卵巢癌患者,均进行肿瘤细胞减灭术,按化疗时间分为对照组(术前未化疗,n=50例)和观察组(术前新辅助化疗,n=50例),观察两组手术情况及治疗效果。结果新辅助化疗有效缓解率为62.00%,且观察组手术时间、术中出血量均优于对照组,观察组最佳减灭率高于对照组(P<0.05)。结论在晚期卵巢癌治疗中,严格掌握新辅助化疗的临床适应证,选择合适的化疗方案,可提高其治疗效果。

Objective To investigate the effect of neoadjuvant chemotherapy in advanced ovarian cancer. Meth-ods Sampled 100 patients with advanced ovarian cancer admitted to our hospital from January 2013 to January 2016,underwent cytoreductive surgery, According to the time of chemotherapy, the patients were divided into control group(n=50 cases without chemotherapy before operation) and observation group (n=50 cases with neoadjuvant chemother-apy before operation), observe two groups of operation and treatment effect. Results The effective remission rate ofneoadjuvant chemotherapy was 62.00%, and the operation time and blood loss of the observation group were betterthan that of the control group. The best reduction rate of the observation group was higher than that of the controlgroup (P<0.05). Conclusion In the treatment of advanced ovarian cancer, it is strictly control the clinical indications ofneoadjuvant chemotherapy, select the appropriate chemotherapy regimen, which can improve the treatment effect.